Medical Research
(H12)
IRS Verified
DX Registered
990 on File
ADENOID CYSTIC CARCINOMA RESEARCHFOUNDATION
Financial strength (30%)
89/100
Reliability (20%)
55/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2023
$1.9M
Total Revenue
$1.9M
Total Expenses
$2.5M
Net Assets
3
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
92.1%
Fundraising Efficiency
N/A
Operating Reserve
16.30x
Liability-to-Asset
5.5%
Revenue Diversification
55.7%
Executive Compensation
$150K
Compared with Peers
FY 2023
Compared with 481 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2023.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
92.1% | 82.4% |
P10P90
|
Top quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
6.3% | 12.0% |
P10P90
|
Top quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
1.6% | 1.0% |
P10P90
|
Below median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
16.3 mo | 15.1 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
5.5% | 11.5% |
P10P90
|
Above median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
55.7% | 93.0% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
36.6% | 7.0% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
15.7% | 12.7% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
1.1% | 0.1% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2023 | $1.9M | $1.9M | $2.5M | 92.1% | 3 |
| 2022 | $1.4M | $1.6M | $2.5M | 93.2% | 2 |
| 2021 | $2.4M | $2.1M | N/A | — | 2 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.